

Enc 2 Appx 1

Company Response to the Preliminary Appraisal Recommendation opicapone (Ongentys®) 50 mg hard capsule

The following response was communicated via email from Bial Pharma UK Ltd:

Opicapone (Ongentys®) as adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Thank you once again for informing us of the outcome of the New Medicines Group (NMG) meeting on 10th April 2024.

Bial does not wish to make a formal response to the Preliminary Assessment Recommendation (PAR).